At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 313 enrolled
Drug / intervention
Cabiralizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
In Brief
A Phase 1 clinical trial evaluating Cabiralizumab and Nivolumab for Advanced Solid Tumors and 6 related conditions. Completed, enrolled 313 participants across 39 sites.
Detailed Summary
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionNov 2019
TodayJul 2026
First PostedAug 18, 2015
Enrollment StartSep 8, 2015
Primary CompletionNov 18, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.9 years ago
Interventions
Cabiralizumabbiological
Solution for IV administration
Nivolumabbiological
Solution for IV administration